Yassin Mohamed Taha, Al-Otibi Fatimah O, Al-Sahli Sarah A, El-Wetidy Mohammad S, Mohamed Sara
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia.
King Salman Center for Disability Research, Riyadh 11614, Saudi Arabia.
Cancers (Basel). 2024 Dec 19;16(24):4234. doi: 10.3390/cancers16244234.
Cancer remains a predominant global health concern, necessitating effective treatment options. Conventional cancer therapies, particularly chemotherapy, often face constraints such as low selectivity, insufficient solubility, and multidrug resistance (MDR), which diminish effectiveness and exacerbate negative effects. Metal oxide nanoparticles (MONPs), such as iron oxide, zinc oxide, and copper oxide, offer a promising solution by enhancing targeted drug delivery, reducing systemic toxicity, and mitigating chemotherapy-induced disabilities like neurotoxicity and cardiotoxicity. Nanocarriers conjugated with drugs can improve drug delivery within the body and enhance their circulation in the bloodstream. Recent advancements in MONP synthesis and functionalization have further improved their stability and drug-loading capacity, making them a valuable tool in cancer treatment. MONPs have distinctive physicochemical characteristics, enabling better imaging, drug encapsulation, and targeted medication delivery to cancerous cells. These nanocarriers enhance treatment effectiveness through focused and controlled drug release, reducing off-target effects and addressing drug resistance. This review aims to explore the potential of MONPs as efficient nanocarriers for anticancer drugs, addressing limitations of traditional chemotherapy such as poor specificity, systemic toxicity, and drug resistance. Additionally, the review discusses recent advancements in MONP synthesis and functionalization, which enhance their stability, drug-loading capacity, and compatibility.
癌症仍然是全球主要的健康问题，需要有效的治疗方案。传统的癌症治疗方法，尤其是化疗，常常面临诸如选择性低、溶解度不足和多药耐药性（MDR）等限制，这些限制会降低疗效并加剧负面影响。金属氧化物纳米颗粒（MONP），如氧化铁、氧化锌和氧化铜，通过增强靶向药物递送、降低全身毒性以及减轻化疗引起的神经毒性和心脏毒性等残疾，提供了一个有前景的解决方案。与药物共轭的纳米载体可以改善药物在体内的递送并增强其在血液中的循环。MONP合成和功能化的最新进展进一步提高了它们的稳定性和载药能力，使其成为癌症治疗中的一种有价值的工具。MONP具有独特的物理化学特性，能够实现更好的成像、药物封装以及向癌细胞的靶向给药。这些纳米载体通过聚焦和可控的药物释放提高治疗效果，减少脱靶效应并解决耐药性问题。本综述旨在探讨MONP作为抗癌药物高效纳米载体的潜力，解决传统化疗的局限性，如特异性差、全身毒性和耐药性。此外，该综述还讨论了MONP合成和功能化的最新进展，这些进展增强了它们的稳定性、载药能力和兼容性。
